The clinical presentation of MOG antibody positive patients with MS pattern II pathology varies, and includes cases with CIS, MS, NMOSD, recurrent LETM followed by tumefactive lesions, and atypical inflammatory demyelinating CNS syndromes (47, 58, 90–93, 94). The gene discussed is MOG; the disease is myeloid sarcoma.